ImmunityBio, Inc. (IBRX) stock
Close on Nov 11, 2026Market cap $7.07BP/E –Yield –
ImmunityBio, Inc. grew revenue 121.2% to $182.57M over the twelve months to Sep 30, 2026. Free cash flow was -$296.69M. At the latest close the market valued the company at $7.07B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $7.07B
- P/E ratio
- –
- Price to sales
- 38.72
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -4.20%
Fundamentals
- Revenue
- $182.57M
- Net income
- -$1.11B
- EPS, diluted
- -$1.08
- Free cash flow
- -$296.69M
- Book value per share
- -$1.08
- Diluted shares
- 1.06B
Trading
- Next earnings
- Jan 14, 2027 (estimated, before the open)
- Previous close
- $6.75
- Open
- $6.80
- Day's range
- $6.51 – $6.85
- Volume
- 11,967,530
- Average volume (20 days)
- 13,699,233
- Index membership
- Russell 2000 (since Mar 2021), Russell 3000 (since May 2021)
- Beta (5 years)
- 1.56
- 52-week range
- $1.95 – $12.43
- RSI (14 days)
- 36.1
- Volatility (1 year)
- 109.2%
- Relative volume
- 1.05×
- WACC
- 12.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IBRX | S&P 500 | Difference | IBRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -36.5% | -2.4% | −34.1 pts | ||
| 3 months | -12.2% | -1.2% | −11.1 pts | ||
| Year to date | +236.9% | +12.3% | +224.6 pts | ||
| 1 year | +211.7% | +12.4% | +199.2 pts | ||
| 3 years | +114.5% | +78.8% | +35.7 pts | +29.0% | +21.4% |
| 5 years | -14.7% | +75.2% | −89.9 pts | -3.1% | +11.9% |
| 10 years | -11.9% | +311.1% | −323.0 pts | -1.3% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ImmunityBio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Update
About ImmunityBio
Biological Products, (No Diagnostic Substances)
ImmunityBio, Inc. is a biotechnology company that creates and commercializes immunotherapies aimed at activating both the innate and adaptive immune systems to treat cancers and infectious diseases. Its core technology, the Cancer BioShield platform, integrates cytokine fusion proteins, adenovirus-vectored vaccine delivery systems, and natural killer (NK) cell therapies to stimulate critical lymphocytes and generate lasting immune memory. The company's lead commercial product is ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist antibody-cytokine fusion protein. Customers include adult patients suffering from non-muscle invasive bladder cancer unresponsive to standard therapy, as well as those with progressing metastatic non-small cell lung cancer receiving combination checkpoint inhibitor treatments.
Company profile, executives and historyImmunityBio stock: common questions
What is ImmunityBio's stock price?
IBRX closed at $6.67 on Nov 11, 2026, down 1.11% on the day. Over the past 52 weeks it traded between $1.95 and $12.43.
What is ImmunityBio's market cap?
ImmunityBio was worth $7.07B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IBRX's P/E ratio?
ImmunityBio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.08), so it has no meaningful P/E ratio.
How much revenue does ImmunityBio make?
ImmunityBio reported revenue of $182.57M for the twelve months to Sep 30, 2026, up 121.2% from a year earlier.
Does ImmunityBio pay a dividend?
No. ImmunityBio has not paid a cash dividend over the last twelve months.
When does ImmunityBio report earnings next?
ImmunityBio is expected to report Q4 FY2026 results on Jan 14, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IBRX stock performed over the past year?
Including dividends, IBRX returned +211.7% over the past year, against +12.4% for the S&P 500.
How many IBRX shares are sold short?
126M shares were sold short at the latest FINRA report, 48.05% of the float, or 10.8 days of average trading volume.
Who are ImmunityBio's competitors?
Companies most similar to ImmunityBio by business, industry and size include IMCR, IOVA, AUTL, ADPT, ADAPY.
See a number that looks wrong?